Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 2, 2025Therapeutic Advances in Medical OncologyOpen Access

Nab-paclitaxel-based chemotherapy with or without anti-PD-(L)1 immunotherapy as a second-line treatment for advanced biliary tract cancer: a real-world retrospective study

View Full Paper
Ask AI
Bookmark
Share

Authors

NZNan ZhouXLXinyi LiMGMingyou Gao

Discussion

Loading...

Member takes

Overview

Retrospective study shows nab-paclitaxel-based treatment improves overall survival in biliary tract cancer, suggesting benefits of anti-PD-(L)1.

Key Points

  • Median overall survival for patients receiving nab-paclitaxel was 15.17 months, indicating substantial treatment efficacy.
  • Including anti-PD-(L)1 therapy led to an observed increase in response rate to 29.3%, but no significant improvements were noted.
  • The real-world retrospective analysis focused on second-line treatment for advanced biliary tract cancer between 2018 and 2023.
  • Treatment outcomes suggest nab-paclitaxel regimens may have a positive impact, warranting further study on anti-PD-(L)1 benefits.

Cite This Study

Zhou et al. (2025) studied this question.

synapsesocial.com/papers/692e3d796c9b3ab28c18705bhttps://doi.org/10.1177/17588359251389753
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Nab-paclitaxel plus cisplatin versus gemcitabine plus cisplatin as first-line treatment in advanced biliary tract cancer: results of a multicentre, randomised, phase II trial2025
  2. 2Role of the immunotherapy in the treatment of biliary tract cancers: Review of current clinical trials and retrospective analysis2025
  3. 3Real-World Evidence of the Efficacy and Safety of Second-Line Therapy After Gemcitabine and Nab-Paclitaxel for Patients with Metastatic Pancreatic Cancer2025
  4. 4Efficacy and safety of durvalumab and gemcitabine-based chemotherapy combined with or without lenvatinib in advanced biliary tract cancer: A retrospective real-world study2025
  5. 5Comparative efficacy and safety of targeted therapeutics or immunotherapy agents combined with chemotherapy as first-line treatment for advanced biliary tract cancer: a systematic review and network meta-analysis2025